Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Pharming Group N.V. Trends and Insights

Biotech SG&A Expenses: Alnylam vs. Pharming, A Decade of Growth

__timestampAlnylam Pharmaceuticals, Inc.Pharming Group N.V.
Wednesday, January 1, 2014445260004042025
Thursday, January 1, 2015606100005279557
Friday, January 1, 2016893540008073913
Sunday, January 1, 201719936500044864073
Monday, January 1, 201838235900053488904
Tuesday, January 1, 201947900500065896361
Wednesday, January 1, 202058842000069968267
Friday, January 1, 202162063900092047281
Saturday, January 1, 2022770658000131819000
Sunday, January 1, 202379564600087501000
Monday, January 1, 2024975526000
Loading chart...

Data in motion

SG&A Expenses: A Tale of Two Biotechs

In the competitive world of biotechnology, managing operational costs is crucial for success. Alnylam Pharmaceuticals, Inc. and Pharming Group N.V. offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses over the past decade.

Alnylam Pharmaceuticals, Inc.

From 2014 to 2023, Alnylam's SG&A expenses surged by over 1,600%, reflecting its aggressive growth strategy and expansion efforts. By 2023, their expenses reached nearly $796 million, a testament to their commitment to innovation and market presence.

Pharming Group N.V.

In contrast, Pharming Group N.V. maintained a more conservative approach, with SG&A expenses increasing by approximately 2,100% over the same period. Their 2023 expenses were around $88 million, indicating a more measured growth trajectory.

This comparison highlights the diverse strategies employed by biotech firms in navigating the complex landscape of drug development and commercialization.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025